160 related articles for article (PubMed ID: 195342)
1. Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat.
Lazarow PB
Science; 1977 Aug; 197(4303):580-1. PubMed ID: 195342
[TBL] [Abstract][Full Text] [Related]
2. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate.
Reddy JK; Krishnakantha TP
Science; 1975 Nov; 190(4216):787-9. PubMed ID: 1198095
[TBL] [Abstract][Full Text] [Related]
3. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
[TBL] [Abstract][Full Text] [Related]
4. Effects of hypolipidemic drugs on hepatic CoA.
Halvorsen O
Biochem Pharmacol; 1983 Mar; 32(6):1126-8. PubMed ID: 6838659
[No Abstract] [Full Text] [Related]
5. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
Orton TC; Parker GL
Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
[TBL] [Abstract][Full Text] [Related]
6. Hepatic catalase is not essential for the hypolipidemic action of peroxisome proliferators.
Reddy JK; Moody DE; Azarnoff DL; Rao MS
Proc Soc Exp Biol Med; 1977 Apr; 154(4):483-7. PubMed ID: 859854
[No Abstract] [Full Text] [Related]
7. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug.
Lazarow PB; De Duve C
Proc Natl Acad Sci U S A; 1976 Jun; 73(6):2043-6. PubMed ID: 180535
[TBL] [Abstract][Full Text] [Related]
8. Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat.
Lazarow PB; Shio H; Leroy-Houyet MA
J Lipid Res; 1982 Feb; 23(2):317-26. PubMed ID: 7077146
[TBL] [Abstract][Full Text] [Related]
9. Increased liver-specific expression of catalase in transgenic mice.
Nilakantan V; Li Y; Spear BT; Glauert HP
Ann N Y Acad Sci; 1996 Dec; 804():542-53. PubMed ID: 8993572
[No Abstract] [Full Text] [Related]
10. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
11. Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents.
Moody DE; Reddy JK; Azarnoff DL
Biochem Pharmacol; 1984 Aug; 33(16):2591-7. PubMed ID: 6431985
[TBL] [Abstract][Full Text] [Related]
12. Clofibrate does not induce peroxisomal 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoyl coenzyme A oxidation in rat liver. Evidence that this reaction is catalyzed by an enzyme system different from that of peroxisomal acyl-coenzyme A oxidation.
Pedersen JI; Hvattum E; Flatabø T; Björkhem I
Biochem Int; 1988 Jul; 17(1):163-9. PubMed ID: 3190714
[TBL] [Abstract][Full Text] [Related]
13. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
Reddy JK; Azarnoff DL; Sirtori CR
Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
[TBL] [Abstract][Full Text] [Related]
14. Involvement of calmodulin- and protein kinase C-related mechanism in an induction process of peroxisomal fatty acid oxidation-related enzymes by hypolipidemic peroxisome proliferators.
Watanabe T; Okawa S; Itoga H; Imanaka T; Suga T
Biochim Biophys Acta; 1992 Apr; 1135(1):84-90. PubMed ID: 1591274
[TBL] [Abstract][Full Text] [Related]
15. The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
MacDonald RS; Swan PB
Biochim Biophys Acta; 1986 Feb; 880(2-3):153-60. PubMed ID: 3942787
[TBL] [Abstract][Full Text] [Related]
16. Hepatic effect of two hypolipidemic drugs in rats.
Magnusson G; Magnusson O
Exp Pathol (Jena); 1977; 13(2-3):180-7. PubMed ID: 913535
[TBL] [Abstract][Full Text] [Related]
17. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates.
Alegret M; Ferrando R; Vázquez M; Adzet T; Merlos M; Laguna JC
Br J Pharmacol; 1994 Jun; 112(2):551-6. PubMed ID: 7915611
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid metabolism in liver of rats treated with hypolipidemic sulphur-substituted fatty acid analogues.
Asiedu D; Aarsland A; Skorve J; Svardal AM; Berge RK
Biochim Biophys Acta; 1990 May; 1044(2):211-21. PubMed ID: 1971517
[TBL] [Abstract][Full Text] [Related]
19. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.
Amacher DE; Beck R; Schomaker SJ; Kenny CV
Toxicol Appl Pharmacol; 1997 Jan; 142(1):143-50. PubMed ID: 9007043
[TBL] [Abstract][Full Text] [Related]
20. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes.
Moody DE; Reddy JK
Am J Pathol; 1978 Feb; 90(2):435-46. PubMed ID: 623209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
